A positive result of treating patients with coronavirus with the anti-rheumatoid arthritis drug Tocilizumab (Tocilizumab) manufactured by the pharmaceutical company Roche was reported in Italy.
Hospitals request the Italian Medical Agency (AIFA) for approval of such a treatment plan. This was reported by Vincenzo Montesarchio, a specialist in infectious diseases at the Cotugno Hospital in Naples, LA Republica reports.
“Four patients in life support in the emergency ward feel better,” Vincenzo Montesarchio explains. “Currently we are waiting for a rheumatologist to estimate his condition before we extubate the patient.”
Three out of four patients who got Tocilizumab treatment since Saturday show an excellent response for the medication. These four have not been under the intensive therapy, Montesarchio underlines, they were hospitalized in critical condition.
The Prato hotel also sent another request for use of Tocilizumab for some patients on March 16.
Another encouraging results come from Cosenza hospital – two patients respond to the treatment positively.
In Apulia some patients are also getting Tocilizumab treatment.
The medication does not fight the coronavirus infection and it was only tested for seriously ill patients. According to the first data from Italy, Tocilizumab gives good results in hard cases of interstitial pneumonia. Thus Apulia region requested the medications from Roche and has already got the stock.
As we reported earlier, over 27,000 people have contracted the infection and 2,470 deaths have been reported in Italy — the most affected country outside China.